The soft-sided Recon coolers range in size between 12 and 21 liters (19 and 35 cans) and have been designed for squeezing into vehicle spaces like backseats and footwells. They use zipper-free ...

AstraZeneca and Daiichi Sankyo’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes ...

TOKYO & BASKING RIDGE, N.J. - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) announced positive results from the phase 3 DESTINY-Breast09 trial, indicating that their drug ENHERTU®, ...

Company News Published 06/02/2025, 08:13 AM 0 ENHERTU shows promise in metastatic breast cancer trial 4568 2.24% ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but previously untreated breast cancer — study results reported ...

TOKYO & BASKING RIDGE, N.J., May 31, 2025--ENHERTU Reduced Risk of Death by 30% as 2L Therapy in Patients w/HER2+ Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial ...

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage HER2-positive breast cancer. Read more here.

The Recon 70 is available in a wide range of colours, and the Blue Camo variety mine came in looks quite pretty. The top of the earcup is the camo design, while the bottom is a solid navy style blue.

AstraZeneca's Enhertu shows significant success in late-stage trials as a first-line treatment for HER2-positive metastatic breast cancer. Read more here.

Enhertu was first approved by the FDA in 2019 as a third-line treatment for HER2-positive metastatic breast cancer. The therapy expanded its approved use to second-line treatment of this type ...